Review
Open access
Jul 2026
Rewriting CAR-T cell fate: CRISPR/Cas gene editing for solid tumor therapy
Recent advances in the application of CRISPR/Cas gene editing technology to enhance the antitumor activity of CAR-T cells against solid tumors are summarized and the key challenges currently faced are discussed.
Wenjing Liu, Jiayi Gu, Chenghao Xie et al.
· Frontiers in Immunology · 0 citations